Reimbursement
and Support for Dermacyte AC Matrix Amniotic Membrane Allograft
Merakris offers a comprehensive reimbursement support for providers using Dermacyte AC Matrix Amniotic Membrane Allograft. To get your copy, complete this form.
Dermacyte AC Matrix Amniotic Membrane Allograft is regulated by the U.S. Food and Drug Administration (FDA) as a minimally manipulated human allograft tissue under its Human Cells, Tissues, and Tissue-Based Products (HCT/P) guidelines, subject to Section 361 of the Public Health Service Act and 21 CFR 1271.